Abstracts Archive - Page 1253 of 2425 - ACR Meeting Abstracts

Abstract Number: 712 • 2017 ACR/ARHP Annual Meeting
Novel Electronic Health Record Method Reveals That dsDNA Antibody-Negative Systemic Lupus Erythematosus Is Associated with Pain, Sleep, and Mood Disorders
April Barnado¹, Robert Carroll², Carolyn Casey³, Joshua C. Denny² and Leslie Crofford¹, ¹Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, ³Lehigh Valley Health Network, Allentown, PA
Background/Purpose: Systemic lupus is a heterogeneous disease with diverse presentations. Studies have shown that dsDNA antibodies associate with renal disease. However, less is known about…
Abstract Number: 713 • 2017 ACR/ARHP Annual Meeting
Long-Term Outcomes in Prolonged Low Disease Activity Are Comparable to Complete Clinical Remission in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna D Gladman², Zahi Touma³, Jiandong Su⁴, Nicole Anderson² and Murray Urowitz⁵, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Prolonged clinical remission is a desirable, though rare outcome in systemic lupus erythematosus (SLE). We recently showed that low disease activity (LDA) state confers…
Abstract Number: 714 • 2017 ACR/ARHP Annual Meeting
Prolonged Antimalarial Treatment Is Associated with Increased Risk for Elevated Myocardial Biomarkers in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna D Gladman², Paula Harvey³, Shadi Akhtari³, Jiandong Su⁴ and Murray Urowitz², ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Antimalarial (AM)-induced cardiomyopathy (AMIC) has been rarely reported in systemic lupus erythematosus (SLE). However, given the large number of patients treated, it seems possible…
Abstract Number: 715 • 2017 ACR/ARHP Annual Meeting
Long-Term Outcome of Demyelnating Syndrome in Systemic Lupus Erythematosus: A Longitudinal Study
Jamal A. Mikdashi¹ and Ipolia Ramadan², ¹Div of Rheumatology, Univ of Maryland Schl of Med, Baltimore, MD, ²National Institue of Health, Rockville, MD
Background/Purpose: Demyelinating syndromes (DS) in systemic lupus erythematosus (SLE) are characterized by inflammation, demyelination and neurodegeneration. Little is known, however, about the tenet of dissemination…
Abstract Number: 716 • 2017 ACR/ARHP Annual Meeting
Prolonged Exposure to Antiphospholipid Antibodies Is Associated with Endothelial Dysfunction in Patients with Systemic Lupus Erythematosus
In-Woon Baek¹, Yune-Jung Park², Ki-Jo Kim³, Wan-Uk Kim Sr.⁴ and Chul-Soo Cho¹, ¹Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of (South), ²Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Gyeonggido, Korea, Republic of (South), ³Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea, Republic of (South), ⁴The Catholic University of Korea, Department of Internal Medicine, seoul, Korea, Republic of (South)
Background/Purpose: Antiphospholipid syndrome has been shown to be associated with increased cardiovascular mortality, but the role of antiphospholipid antibodies (aPL) on endothelial dysfunction remains elusive.…
Abstract Number: 717 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Neuropsychiatric Systemic Lupus Erythematosus and Its Recurrence
Ryusuke Anan, Yuko Kaneko, Jun Kikuchi and Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Neuropsychiatric involvement in systemic lupus erythematosus (NPSLE) is the leading cause of morbidity and mortality in patients with SLE but not well understood. The…
Abstract Number: 718 • 2017 ACR/ARHP Annual Meeting
Atherosclerotic Vascular Events in a Multinational SLE Inception Cohort: Description and Predictive Risk Factors over a 17 Year Period
Murray Urowitz¹, Dafna D Gladman², Nicole Anderson³ and Jiandong Su⁴, ¹Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: A large multicentre multinational inception cohort was established to study risk factors for atherosclerosis (AS) in SLE. We aim to describe all vascular events…
Abstract Number: 719 • 2017 ACR/ARHP Annual Meeting
Lupus Nephritis in Isolation or Accompanied By Extra-Renal Manifestations: Early Lessons from the Accelerating Medicines Partnership
Judith A. James¹, Michelle Petri², Chaim Putterman³, Betty Diamond⁴, David Wofsy⁵, Chun Hao Lee⁶, Derek Fine⁶, Anna R. Broder⁷, Robert M. Clancy⁸, Peter M. Izmirly⁹, Michael Belmont¹⁰, Nicole Bornkamp¹¹, Anne Davidson¹², Patti Tosta¹³, Kenneth C. Kalunian¹⁴, Meyeon Park¹⁵, Maria Dall'Era¹⁶, Richard Furie¹⁷, Elena Massarotti¹⁸, German T. Hernandez¹⁹, Fernanda Payan-Schober²⁰, Sean M. Connery¹⁹, Diane L. Kamen²¹, Iris Lee²², William Pendergraft III²³, Jennifer H. Anolik²⁴, Ummara Shah²⁵, Soumya Raychaudhuri²⁶, Yvonne C. Lee²⁷, Joel M. Guthridge²⁸, V. Michael Holers²⁹, Paul J. Utz³⁰, Mina Pichavant³¹, Rohit Gupta³¹, Holden T. Maecker³², Michael Weisman³³ and Jill P. Buyon³⁴, ¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ⁴Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, ⁵Rheumatology, UCSF, San Francisco, CA, ⁶Johns Hopkins University, Baltimore, MD, ⁷Albert Einstein College of Medicine, Bronx, NY, ⁸NYU School of Medicine, New York, NY, ⁹New York University School of Medicine, New York, NY, ¹⁰New York University, NYC, NY, ¹¹Medicine, New York University School of Medicine, New York, NY, ¹²Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ¹³Immune Tolerance Network, San Francisco, CA, ¹⁴Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ¹⁵University of California San Francisco, San Francisco, CA, ¹⁶Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ¹⁷Hofstra Northwell, Manhasset, NY, ¹⁸Brigham and Women's Hospital, Boston, MA, ¹⁹Texas Tech University HSC El Paso, El Paso, TX, ²⁰Texas Tech University HSC El Paso, El Paso, TX, ²¹Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ²²Temple University Hospital, Philadelphia, PA, ²³Kidney Center, University of North Carolina, Chapel Hill, NC, ²⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²⁵Division of Rheumatology, New York University School of Medicine, NYC, NY, ²⁶Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²⁷Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²⁸Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK, ²⁹Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ³⁰Medicine, Stanford University School of Medicine, Stanford, CA, ³¹Stanford University, Stanford, CA, ³²Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ³³Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, ³⁴Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Lupus nephritis (LN) remains one of the most serious complications of SLE, occurring in up to 50% of patients. Current LN treatments are not…
Abstract Number: 720 • 2017 ACR/ARHP Annual Meeting
Ambulatory Blood Pressure and Skin Sodium Concentrations in Patients with Systemic Lupus Erythematosus
Daniel Carranza Leon¹, Cecilia P. Chung¹, Michelle J. Ormseth², Annette M. Oeser³, Ping Wang⁴, Adriana Marton¹, Jens Titze³ and C. Michael Stein¹, ¹Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Rheumatology, Vanderbilt Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Radiology, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Ambulatory 24-hour blood pressure and nocturnal blood pressure measurements are better predictors of cardiovascular risk than office blood pressure. Patients with systemic lupus erythematosus…
Abstract Number: 721 • 2017 ACR/ARHP Annual Meeting
Improving the Quality of Care in Systemic Lupus Erythematosis (SLE) through Time-Structured, Information Technology-Enhanced, Quality Improvement Indicator-Driven Patient Management
Frank Migliore¹, Robert Quinet², William E. Davis³, Daniel Wray⁴, Timothy Hilbun⁵ and Magdelena Budziakowska¹, ¹Ochsner Clinic Foundation, New Orleans, LA, ²Rheumatology, Ochsner Medical Center, New Orleans, LA, ³University of Queensland School of Medicine, Brisbane, Australia, ⁴Twine Clinical Consulting LLC, Park City, UT, ⁵IS ANALYTICS NOM, Ochsner Medical Center, New Orleans, LA
Background/Purpose: Gaps exist in SLE patient care in monitoring and management of comorbidities, treatment related toxicities, and disease activity, suggesting a lack of well-defined systems…
Abstract Number: 722 • 2017 ACR/ARHP Annual Meeting
Differential Diagnosis of Autoimmune Diseases, Outlier Detection Plus Subgrouping in Clinical Trials By High Content Autoantibody Profiling
Peter Schulz-Knappe, Petra Budde and Hans-Dieter Zucht, Protagen AG, Dortmund, Germany
Background/Purpose: Early diagnosis as well as initiation of successful treatment are two big challenges in the management of patients with autoimmune diseases (AID). Overlap of…
Abstract Number: 723 • 2017 ACR/ARHP Annual Meeting
Incidence and Variability of Cardiovascular Risk Factors in Female Lupus Patients: A 3-Year Follow-up
Carolinne Monção¹, Leticia Martins¹, Marcela Penteado¹, Rodrigo Reis², Fabiana Miranda Moura dos Santos³, CRISTINA COSTA LANNA³, Antônio Luiz Ribeiro⁴ and Rosa Weiss Telles⁴, ¹Hospital das Clinicas, Universidade Federal of Minas Gerais, Belo Horizonte, Brazil, ²Universidade Federal of Minas Gerais, Belo Horizonte, Brazil, ³Medical School, Universidade Federal of Minas Gerais, Brazil, Belo Horizonte, Brazil, ⁴Medical School, Universidade Federal of Minas Gerais, Belo Horizonte, Brazil
Background/Purpose: To evaluate the incidence and variability of traditional coronary artery disease (CAD) risk factors in a cohort of systemic lupus erythematosus (SLE) patients. Methods:…
Abstract Number: 724 • 2017 ACR/ARHP Annual Meeting
Antibodies Against the Chemokine Receptors CXCR3 and CXCR4 Predict Progressive Lung Fibrosis in Systemic Sclerosis (SSc)
Gabriela Riemekasten¹, Elise Siegert² and Harald Heidecke³, ¹Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany, ²Rheumatology and Clinical Immunology, University Hospital Charité, Berlin, Germany, ³CellTrend GmbH Luckenwalde, Luckenwalde, Germany
Background/Purpose: Chemokine receptors CXCR3 and CXCR4 are involved in immune cell migration and in the pathogenesis of inflammatory fibrosis, a key feature of systemic sclerosis…
Abstract Number: 725 • 2017 ACR/ARHP Annual Meeting
Safety and Efficacy of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc) Subjects Treated in an Open-Label Extension of Trial JBT101-SSc-001
Robert F. Spiera¹, Laura K. Hummers², Lorinda Chung³, Tracy M. Frech⁴, Robyn T. Domsic⁵, Vivien Hsu⁶, Daniel E. Furst⁷, Jessica K. Gordon¹, Maureen D. Mayes⁸, Robert W. Simms⁹, Scott Constantine¹⁰ and Barbara White¹⁰, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, ³Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ⁷David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁸Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Anabasum (JBT-101) is a selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses and limits fibrosis in animal models of…
Abstract Number: 726 • 2017 ACR/ARHP Annual Meeting
Performance of the American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (CRISS) in the Scleroderma Lung Study-I
Dinesh Khanna¹, Donald P. Tashkin², Holly Wilhalme² and Chi-hong Tseng³, ¹University of Michigan, Ann Arbor, MI, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: The CRISS has been proposed as a composite outcome measure for trials in systemic sclerosis1. CRISS is a 2-step process that assigns a probability…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].